INOVIO Pharmaceuticals Reports $19.7 Million Net Loss and Seeks Additional Capital

INOVIO Pharmaceuticals, Inc. reported a net loss of $19.7 million for the first quarter of 2026, a slight decrease from the $19.7 million loss recorded in the same period of the previous year. The company did not generate any revenue during the quarter, compared to $65,000 from collaborative arrangements in the first quarter of 2025. Total operating expenses decreased to $21.9 million from $25.1 million year-over-year, primarily due to reduced research and development costs, which fell to $14.1 million from $16.1 million. The decrease in expenses was attributed to lower employee compensation, engineering services, and inventory costs.

As of March 31, 2026, INOVIO's cash, cash equivalents, and short-term investments totaled $37.7 million, down from $58.5 million at the end of 2025. The company reported working capital of $1.5 million, a decrease from $17.5 million at the end of the previous year. The decline in cash reserves raises concerns about the company's ability to fund operations, as it has indicated substantial doubt about its ability to continue as a going concern beyond late 2026 without additional financing. INOVIO has been actively seeking capital through public offerings, including a recent underwritten public offering that raised $16 million in April 2026.

Strategically, INOVIO is focused on advancing its lead product candidate, INO-3107, which is under review by the FDA for accelerated approval as a treatment for recurrent respiratory papillomatosis (RRP). The FDA accepted the Biologics License Application (BLA) for INO-3107 in December 2025, with a target review date set for October 30, 2026. The company is currently engaged in discussions with the FDA regarding the eligibility for accelerated approval, following the agency's request for additional information. INOVIO has also entered into collaborations to evaluate other candidates, including INO-5412 for glioblastoma and INO-3112 for oropharyngeal squamous cell carcinoma.

Operationally, INOVIO has faced challenges, including a significant reduction in its investment in Plumbline Life Sciences, which was valued at $0 as of March 31, 2026, down from $2.1 million at the end of 2025. The company has also been involved in litigation, including a shareholder class action and derivative lawsuits related to its disclosures about the FDA review process. These legal challenges could impact the company's financial condition and operational focus. Looking ahead, INOVIO anticipates needing substantial additional capital to support its ongoing research and development efforts, particularly for INO-3107 and other pipeline candidates, as it continues to navigate a competitive landscape in the biotechnology sector.